Baird Reiterates an 'Outperform' on AMAG Pharmaceuticals (AMAG); Positive IDA Trial De-Risks Major Opportunity

Baird reiterates an 'Outperform' on AMAG Pharmaceuticals (NASDAQ: AMAG) price target of $21.00.

Analyst, Christopher J. Raymond, said, "Breathing a significant sigh of relief, and anticipate shares will be up sharply today, on positive results of the first of two Feraheme trials in IDA. While one could quibble with the communication around this event (shares were off 7% yesterday as investors fretted about what the release would hold), the bottom line is these data have significantly de-risked a label expansion opportunity that roughly doubles Feraheme's applicable market. Remain buyers into the $20 range."

For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.

Shares of AMAG Pharmaceuticals closed at $14.98 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics